Diabetes Injection Pens Market Growing Continually- Due to Increasing Rate of Diabetes Across the World

 

Diabetes Injection Pens are now actually more commonly used to administer oral diabetes medications to people who have difficulty swallowing. These pens permit the diabetics to inject themselves with a dose of the chosen oral diabetes medication. Insulin pumps and vial style pumps tend to be useful for administering insulin shots and there's also single-dose vials which can be stored in a personal bag or small box and taken at an easy time.

There are many different types of Diabetes Injection Pens available from medical supply companies offering a range of options to the consumer. These are constructed with rubber latex or similar flexible material that is durable and resistant to infection. The needles usually are made from sterile stainless but rubber inserts can be found for use with some units. Depending on which brand and kind of diabetes medicine are increasingly being ordered, the pen is going to be embossed with the letter of the patient's first name, the term "diabetic" or another symbol indicating this fact and their personal information.

Market Dynamics

The key factor driving the growth of the diabetes injection pens market may be the rapid increase of diabetes throughout the globe. For instance, according to a 2020 report by CDC approximately 34.2 million everyone was struggling with diabetes. The new cases of diabetes are high among non-Hispanic blacks than non-Hispanic whites and non-Hispanic Asians. Other factors such as for example injuries caused as a result of needle sticks and bacterial infections due to regular usages of syringes are estimated to propel the marketplace growth of the insulin injection pens market.

However, the abundance of insulin patches, and other safer replacement for insulin injection pens are the main restraining factors hindering the growth of the market.

This market is distributed in five regions offering North America, Europe, Asia-Pacific, Middle East, and Africa, and Latin America. Among these North America is estimated to put up an important share of the diabetes injection pens market owing to the increasing rate of type-1 diabetes and the development of new, safer to make use of pens by key players in the region. For instance, according to the Americans with Disabilities Act (ADA), in 2018, approximately 1.25 million everyone was struggling with type 1 diabetes. ADA estimates that around 40,000 people get identified as having Type 1 diabetes every year. The diabetes injection pens market in the Asia Pacific is estimated to witness significant growth owing to the rising concerns on the list of patients and the development and expansion of healthcare sectors.

Competitive Analysis

Key players operating in the global Diabetes Injection Pens market include Jiangsu Delfu Co., Dickinson and Company, Becton, Eli Lilly and Company, Biocon Ltd, AstraZeneca Plc, and Novo Nordisk A/S.

In June 2019, Victoza was the very first non-insulin drug which was approved for children aged 10 years and above for treating type 2 diabetes.